Lotensin, Xenical, Brevibloc Need Continued Pediatric AE Monitoring – Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Pediatric Advisory Committee recommends continued monitoring for an additional year of pediatric adverse events associated with Novartis' anti-hypertensive Lotensin